Alliancebernstein L.P. reduced its position in shares of AveXis, Inc. (NASDAQ:AVXS) by 13.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,420 shares of the company’s stock after selling 1,980 shares during the period. Alliancebernstein L.P.’s holdings in AveXis were worth $944,000 as of its most recent filing with the SEC.
Several other large investors have also recently bought and sold shares of the stock. Quantitative Systematic Strategies LLC acquired a new position in AveXis during the first quarter valued at $201,000. Candriam Luxembourg S.C.A. acquired a new position in AveXis during the first quarter valued at $1,901,000. Swiss National Bank increased its position in AveXis by 3.0% in the first quarter. Swiss National Bank now owns 27,400 shares of the company’s stock valued at $2,083,000 after buying an additional 800 shares during the last quarter. Pictet Asset Management Ltd. increased its position in AveXis by 44.9% in the first quarter. Pictet Asset Management Ltd. now owns 153,606 shares of the company’s stock valued at $11,679,000 after buying an additional 47,588 shares during the last quarter. Finally, Norges Bank acquired a new position in AveXis during the fourth quarter valued at $1,193,000. 90.68% of the stock is currently owned by institutional investors.
Shares of AveXis, Inc. (NASDAQ:AVXS) opened at 89.49 on Friday. AveXis, Inc. has a one year low of $32.31 and a one year high of $97.77. The stock’s market capitalization is $2.48 billion. The stock has a 50 day moving average of $85.66 and a 200-day moving average of $73.89.
AveXis (NASDAQ:AVXS) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($2.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by $1.10. During the same quarter in the previous year, the firm posted ($0.68) earnings per share. Equities analysts forecast that AveXis, Inc. will post ($4.36) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Alliancebernstein L.P. Has $944,000 Stake in AveXis, Inc. (NASDAQ:AVXS)” was first posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://transcriptdaily.com/2017/08/13/alliancebernstein-l-p-has-944000-position-in-avexis-inc-nasdaqavxs-updated.html.
AVXS has been the topic of several research reports. Chardan Capital upped their price objective on shares of AveXis from $102.50 to $130.00 and gave the stock a “buy” rating in a report on Friday. BMO Capital Markets reiterated a “buy” rating and issued a $123.00 target price on shares of AveXis in a report on Friday. Citigroup Inc. set a $100.00 target price on shares of AveXis and gave the company a “buy” rating in a report on Thursday, June 15th. Jefferies Group LLC reiterated a “buy” rating and issued a $92.00 target price on shares of AveXis in a report on Thursday, May 25th. Finally, Zacks Investment Research upgraded shares of AveXis from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $100.70.
In related news, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $81.88, for a total value of $145,746.40. Following the sale, the vice president now owns 1,780 shares in the company, valued at approximately $145,746.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 5,340 shares of company stock worth $434,872 in the last quarter. Company insiders own 18.60% of the company’s stock.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.